CBP-1019 is under clinical development by Coherent Biopharma and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase II drugs for Esophageal Cancer have a 25% phase transition ...
A critical study sheds light on the growing global burden of esophageal cancer, outlining its significant impact and the imperative to identify the driving factors behind its increasing prevalence.
1 Department of Thoracic Surgery, Ganzhou People’s Hospital, Ganzhou, China 2 Department of Oncology, Ganzhou People’s Hospital, Ganzhou, China Background: Immune checkpoint inhibitors (ICIs) have ...